Literature DB >> 20092998

The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy.

Balasingam Vicknasingam1, Suresh Narayanan, Goh Teik Beng, Sharif Mahsufi Mansor.   

Abstract

BACKGROUND: Ketum (krathom) has been mentioned in the literature as a traditional alternative to manage drug withdrawal symptoms though there are no studies indicating its widespread use for this purpose. This study examines the reasons for ketum consumption in the northern areas of peninsular Malaysia where it is widely used.
METHODS: A cross-sectional survey of 136 active users was conducted in the northern states of Kedah and Penang in Malaysia. On-site urine screening was done for other substance use.
FINDINGS: Ketum users were relatively older (mean 38.7 years) than the larger substance using group. Nearly 77% (104 subjects) had previous drug use history, whilst urine screening confirmed 62 subjects were also using other substances. Longer-term users (use >2 years) had higher odds of being married, of consuming more than the average three glasses of ketum a day and reporting better appetite. Short-term users had higher odds of having ever used heroin, testing positive for heroin and of using ketum to reduce addiction to other drugs. Both groups used ketum to reduce their intake of more expensive opiates, to manage withdrawal symptoms and because it was cheaper than heroin. These findings differ from those in neighbouring Thailand where ketum was used primarily to increase physical endurance.
CONCLUSIONS: No previous study has shown the use of ketum to manage opioid withdrawal symptoms except for a single case reported in the US. Ketum was described as affordable, easily available and having no serious side effects despite prolonged use. It also permitted self-treatment that avoids stigmatisation as a drug dependent. The claims of so many subjects on the benefits of ketum merits serious scientific investigation. If prolonged use is safe, the potential for widening the scope and reach of substitution therapy and lowering its cost are tremendous, particularly in developing countries. Copyright (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20092998     DOI: 10.1016/j.drugpo.2009.12.003

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  43 in total

Review 1.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

2.  The Right to Use Kratom from the Psychiatric and Islamic Perspectives.

Authors:  Mohammad Farris Iman Leong Bin Abdullah; Mohd Afifuddin Mohamad; Noor Naemah Abdul Rahman
Journal:  J Relig Health       Date:  2021-04

Review 3.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

4.  Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic.

Authors:  Albert Garcia-Romeu; David J Cox; Kirsten E Smith; Kelly E Dunn; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2020-02-03       Impact factor: 4.492

5.  Discriminative stimulus properties of mitragynine (kratom) in rats.

Authors:  Norsyifa Harun; Zurina Hassan; Visweswaran Navaratnam; Sharif M Mansor; Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2015-01-25       Impact factor: 4.530

6.  The inhibitory effects of mitragynine on P-glycoprotein in vitro.

Authors:  Noradliyanti Rusli; Azimah Amanah; Gurjeet Kaur; Mohd Ilham Adenan; Shaida Fariza Sulaiman; Habibah Abdul Wahab; Mei Lan Tan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-02       Impact factor: 3.000

7.  Abuse liability of mitragynine assessed with a self-administration procedure in rats.

Authors:  Kai Yue; Theresa A Kopajtic; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2018-07-23       Impact factor: 4.530

8.  Anxiolytic-like effects of mitragynine in the open-field and elevated plus-maze tests in rats.

Authors:  Ammar Imad Hazim; Surash Ramanathan; Suhanya Parthasarathy; Mustapha Muzaimi; Sharif Mahsufi Mansor
Journal:  J Physiol Sci       Date:  2014-01-25       Impact factor: 2.781

9.  Assessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats.

Authors:  Norsyifa Harun; Illa Syafiqah Johari; Sharif Mahsufi Mansor; Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2019-12-12       Impact factor: 4.530

10.  Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies.

Authors:  Tamara I King; Abhisheak Sharma; Shyam H Kamble; Francisco León; Erin C Berthold; Raluca Popa; Orélia Cerlati; Boone M Prentice; Lance R McMahon; Christopher R McCurdy; Bonnie A Avery
Journal:  J Pharm Biomed Anal       Date:  2019-12-05       Impact factor: 3.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.